dasatinib

A drug used to treat certain types of chronic myeloid leukemia and acute lymphoblastic leukemia. Dasatinib is also being studied in the treatment of certain other blood diseases and types of cancer. Dasatinib binds to and blocks BCR-ABL and other proteins that help cancer cells grow. It is a type of tyrosine kinase inhibitor. Also called BMS-354825 and Sprycel.

English dictionary of cancer terms . 2015.

Look at other dictionaries:

  • Dasatinib — Systematic (IUPAC) name N (2 chloro 6 methylphenyl) 2 [[6 [4 (2 hydroxyethyl) 1 piperazinyl] 2 methyl 4 pyrimidinyl]amino] 5 thiazole carboxamide monohydrate Clinical data …   Wikipedia

  • Dasatinib — Général No CAS …   Wikipédia en Français

  • Dasatinib — Strukturformel Allgemeines Freiname Dasatinib Andere Namen …   Deutsch Wikipedia

  • dasatinib — noun A particular drug used as a tyrosine kinase inhibitor …   Wiktionary

  • dasatinib — da·sat·i·nib (də săґtĭ nib) a tyrosine kinase inhibitor used as an antineoplastic in treatment of chronic myeloid leukemia and certain types of acute lymphoblastic leukemia; administered orally …   Medical dictionary

  • Bcr-Abl tyrosine-kinase inhibitor — Bcr Abl tyrosine kinase inhibitors (TKI) are the first line therapy for most patients with chronic myelogenous leukemia (CML). In more than 90% cases CML is caused by chromosomal abnormality resulting in the formation of a so called Philadelphia… …   Wikipedia

  • Sprycel — Strukturformel Allgemeines Freiname Dasatinib Andere Namen …   Deutsch Wikipedia

  • Chronische myeloische Leukämie — Klassifikation nach ICD 10 C92.1 Chronische myeloische Leukämie ICD O 9875/3 …   Deutsch Wikipedia

  • Gleevec — Strukturformel Allgemeines Freiname Imatinib Andere Namen 4 [(4 Methylpiperazi …   Deutsch Wikipedia

  • Glivec — Strukturformel Allgemeines Freiname Imatinib Andere Namen 4 [(4 Methylpiperazi …   Deutsch Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.